InflaRx (IFRX) News Today $0.86 -0.05 (-4.97%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.86 +0.00 (+0.12%) As of 08/1/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period InflaRx (IFRX) to Release Earnings on ThursdayAugust 2 at 2:50 AM | marketbeat.comInflaRx (NASDAQ:IFRX) Shares Up 2.8% - Still a Buy?August 1 at 3:15 AM | americanbankingnews.comInflaRx (NASDAQ:IFRX) Trading 2.8% Higher - What's Next?August 1 at 3:10 AM | marketbeat.comInflaRx to Report Second Quarter 2025 Results on August 7, 2025July 31 at 7:30 AM | globenewswire.comInflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data ExpectedJuly 25, 2025 | msn.comInflaRx Announces Receipt of Nasdaq Deficiency Notice ... - MorningstarJuly 12, 2025 | morningstar.comMInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum ...July 12, 2025 | seekingalpha.comInflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 12, 2025 | finanznachrichten.deInflaRx N.V. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price RequirementJuly 11, 2025 | quiverquant.comQInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementJuly 11, 2025 | globenewswire.comInflaRx (NASDAQ:IFRX) Shares Up 2.1% - Here's WhyJuly 10, 2025 | marketbeat.comInflaRx N.V. (IFRX) Latest Stock News & Headlines - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comInflaRx Appoints KPMG as New Auditor Following Shareholder ApprovalJune 27, 2025 | tipranks.comInflaRx N.V. (NASDAQ:IFRX) Short Interest UpdateJune 18, 2025 | marketbeat.comBrokers Issue Forecasts for InflaRx FY2026 EarningsJune 10, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Sees Large Decline in Short InterestJune 4, 2025 | marketbeat.comInflaRx stock rating cut, price target slashed to $2 by Raymond JamesMay 30, 2025 | investing.comInflaRx Earnings Estimates, EPS & Revenue | NASDAQ:IFRX | BenzingaMay 30, 2025 | benzinga.comOppenheimer Has Lowered Expectations for InflaRx (NASDAQ:IFRX) Stock PriceMay 30, 2025 | marketbeat.comInflaRx’s Strategic Shift to INF904: A Promising Focus Amidst Early-Stage UncertaintyMay 29, 2025 | tipranks.comInflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | finanznachrichten.deInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28, 2025 | msn.comInflaRx Stock (IFRX) Plummets 55% on Clinical FailureMay 28, 2025 | tipranks.comInflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin DiseaseMay 28, 2025 | benzinga.comInflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust CorpMay 28, 2025 | marketbeat.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...May 28, 2025 | gurufocus.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28, 2025 | globenewswire.comInflaRx to Participate in Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in InflaRx (NASDAQ:IFRX)May 16, 2025 | marketbeat.comFY2025 EPS Estimates for InflaRx Raised by Cantor FitzgeraldMay 13, 2025 | marketbeat.comQ2 Earnings Forecast for InflaRx Issued By Leerink PartnrsMay 13, 2025 | marketbeat.comInflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)May 11, 2025 | sg.finance.yahoo.comOppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform RecommendationMay 9, 2025 | msn.comOppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...May 8, 2025 | gurufocus.comInflaRx Reports Q1 2025 Financial Results with Reduced LossesMay 7, 2025 | tipranks.comInflaRx N.V.: InflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finanznachrichten.deInflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | globenewswire.com2IFRX : Preview: InflaRx's EarningsMay 6, 2025 | benzinga.comRaymond James Financial Inc. Makes New Investment in InflaRx (NASDAQ:IFRX)May 5, 2025 | marketbeat.comInflaRx (IFRX) Projected to Post Quarterly Earnings on WednesdayMay 4, 2025 | marketbeat.comCantor Fitzgerald Forecasts InflaRx FY2025 EarningsMay 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage on InflaRx (NASDAQ:IFRX)May 1, 2025 | marketbeat.comInflaRx to Report First Quarter 2025 Results on May 7, 2025 | IFRX Stock NewsApril 30, 2025 | gurufocus.comInflaRx to Report First Quarter 2025 Results on May 7, 2025April 30, 2025 | gurufocus.comInflaRx to Report First Quarter 2025 Results on May 7, 2025April 30, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight RecommendationApril 30, 2025 | msn.comBiotech Shares Jump As Institutional Coverage Begins With Positive OutlookApril 29, 2025 | msn.comInflaRx Approves Key Resolutions at Annual Shareholder MeetingApril 24, 2025 | tipranks.comEversept Partners LP Has $1.22 Million Stock Position in InflaRx (NASDAQ:IFRX)April 24, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Short Interest Up 36.8% in MarchApril 21, 2025 | marketbeat.com Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.190.45▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼42▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rapt Therapeutics News Today ProQR Therapeutics News Today Eledon Pharmaceuticals News Today MediWound News Today Ventyx Biosciences News Today DiaMedica Therapeutics News Today 4D Molecular Therapeutics News Today Y-mAbs Therapeutics News Today Bright Minds Biosciences News Today Alumis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
